Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
Merck Sharp & Dohme (Australia)
Administration route
Intramuscular injection
Subcutaneous injection
Vaccine group
Monovalent vaccines
Description:
Registered for use in people aged ≥12 months.
Monovalent varicella vaccine
Lyophilised powder in a monodose vial with a pre-filled diluent syringe.
Each 0.5 mL reconstituted dose contains:
- ≥1350 plaque-forming units of live attenuated varicella-zoster virus (Oka/Merck strain)
- 18 mg sucrose
- 8.9 mg hydrolysed porcine gelatin
- 3.6 mg urea
- 0.36 mg monosodium glutamate monohydrate
- residual components of MRC-5 cells
Also contains traces of:
- neomycin
- bovine serum
For Product Information and Consumer Medicine Information about Varivax visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Page history
Last updated
Last reviewed
Related diseases